CXCR4/SDF1 interaction inhibits the primordial to primary follicle transition in the neonatal mouse ovary.
The molecular mechanisms behind the entry of the primordial follicle into the growing follicle pool remain poorly understood. To investigate this process further, a microarray-based comparison was undertaken between 2-day postpartum mouse ovaries consisting of primordial follicles/naked oocytes only and those with both primordial follicles and newly activated follicles (7-day postpartum). Gene candidates identified included the chemoattractive cytokine stromal derived factor-1 (SDF1) and its receptor CXCR4. SDF1 and CXCR4 have been implicated in a variety of physiological processes including the migration of embryonic germ cells to the gonads. SDF1-alpha expression increased with the developmental stage of the follicle. Embryonic expression was found to be dichotomous post-germ cell migration, with low expression in the female. Immunohistochemical studies nonetheless indicate that the autocrine pattern of expression ligand and receptor begins during embryonic life. Addition of recombinant SDF1-alpha to neonatal mouse ovaries in vitro resulted in significantly higher follicle densities than for control ovaries. TUNEL analysis indicated no detectable difference in populations of apoptotic cells of treated or control ovaries. Treated ovaries also contained a significantly lower percentage of activated follicles as determined by measurement of oocyte diameter and morphological analysis. Treatment of cultured ovaries with an inhibitor of SDF1-alpha, AMD3100, ablated the effect of SDF1-alpha. By retaining follicles in an unactivated state, SDF1/CXCR4 signaling may play an important role in maintaining the size and longevity of the primordial follicle pool.
Holt
Janet E
JE
Reproductive Science Group, Discipline of Biological Science, School of Environmental and Life Sciences, University of Newcastle, Callaghan, NSW 2308, Australia.
Jackson
Andrew
A
Roman
Shaun D
SD
Aitken
R John
RJ
Koopman
Peter
P
McLaughlin
Eileen A
EA
D000818:Animals; D000831:Animals, Newborn; D001483:Base Sequence; D001596:Benzylamines; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000037:antagonists & inhibitors / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D000080027:Cyclams; D018076:DNA, Complementary / Q000235:genetics; D005260:Female; D006571:Heterocyclic Compounds / Q000494:pharmacology; D008297:Male; D051379:Mice; D009865:Oocytes / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D006080:Ovarian Follicle / Q000187:drug effects / Q000196:embryology / Q000254:growth & development / Q000378:metabolism; D010053:Ovary / Q000187:drug effects / Q000196:embryology / Q000254:growth & development* / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013737:Testis / Q000196:embryology / Q000254:growth & development / Q000378:metabolism
D001596:Benzylamines; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; C515256:Cxcl12 protein, mouse; D000080027:Cyclams; D018076:DNA, Complementary; D006571:Heterocyclic Compounds; D012333:RNA, Messenger; D019718:Receptors, CXCR4; D011994:Recombinant Proteins; C088327:plerixafor